Eight patients with psoriatic arthritis entered an open study to determine the efficacy of oral cyclosporin A for their treatment. The starting dose was 3.5 mg/kg daily. Findings after the first six months are reported. One patient withdrew from the study after five months because of tremors, general malaise, and lack of improvement. Seven patients continued through the study, and 
There is now strong circumstantial evidence that psoriatic skin lesions occur when CD4+ T lymphocytes infitrate the epidermis of genetically susceptible subjects. [1] [2] [3] The genetic factors predisposing to the psoriatic epidermal response have not been characterised, but are likely to entail abnormal homeostatic control of keratinocyte growth, including hyperproliferative response to products of activated T lymphocytes. 4 It has now been conclusively shown that cyclosporin A is effective in clearing psoriatic skin lesions. ' There was a close correlation between improvement in the arthritis and the skin lesions. Five patients had more than 20% of their skin affected (range 20-80%) at entry. After three months' treatment these lesions had improved by 70-82% in all these patients. This improvement continued throughout the study, and the skin lesions had almost disappeared after six months. Six patients were taking nonsteroidal anti-inflammatory drugs at entrythree were able to discontinue this treatment and one could reduce the dose by half.
Of the seven patients who remained in the study, only one required the higher dose of 5 Months tension, but their diastolic pressure did not exceed 100 mmHg, and all responded to treatment with frusemide or calcium blocking
agents.
An increase in serum creatinine by 50% above the baseline value occurred on four occasions in three patients (once in two patients and twice in one patient), and the highest serum creatinine value was 130 Ftmol/l. The rise in creatinine was reversible in all instances when the cyclosporin A dose was temporarily reduced by a quarter. The table shows the mean serum creatinine values at entry and after two, three, and six months.
Mild microscopic haematuria (two to five red blood cells on one occasion) was found in one patient and mild cylindruria (one to five granular casts on several occasions) was found in two patients. There was no other evidence of kidney disease in these patients.
One patient developed mild gingival hyperplasia, which resolved with 25% reduction in the cyclosporin A dose. In one patient a threefold increase in S-aspartate aminotransferase was noted after six months, which returned to normal with 25% reduction in the cyclosporin A dose. It was not necessary to reduce the cyclosporin A dose because of high cyclosporin A blood concentrations. agents and the similarity between the nephrotoxic effects of non-steroidal anti-inflammatory agents and cyclosporin A has been pointed out. 15 A higher incidence of increase in serum creatinine and hypertension has been reported in patients with rheumatoid arthritis receiving cyclosporin A. 2 This is probably due to a higher dose of cyclosporin A, concomitant use of nonsteroidal anti-inflammatory agents, and possibly also older patients. Therefore it may be important to encourage patients with arthritis to reduce their intake of non-steroidal drugs during treatment with cyclosporin A.
The results of this study confirm the efficacy of cyclosporin A on skin manifestations of psoriasis and suggest that this drug may be equally effective for psoriatic arthritis. A close correlation was found between improvement in the indices for arthritis and improvement in skin, suggesting that similar pathogenic mechanisms are functioning in both sites.
Therefore we are currently working on phase 2 of this study, but the findings presented in this paper indicate that a randomised controlled trial of cyclosporin A for psoriatic arthritis is justified.
